Risk factors for disseminated intravascular coagulation in patients with lung cancer

Autor:	Hideyuki Satoh, Yasutsugu Fukushima, Naruo Yoshida, Hiroyoshi Watanabe, Kei Sugitate, Sadaaki Shiromori, Kentaro Nakano, Kumiya Sugiyama, Ryosuke Souma, Hirokuni Hirata, Tomoshige Wakayama, Shingo Tokita, Hajime Arifuku, Kenya Koyama, Masamitsu Tatewaki
Rok vydání:	2018
Předmět:	0301 basic medicine Pulmonary and Respiratory Medicine Disseminated intravascular coagulation medicine.medical_specialty business.industry Respiratory disease Cancer General Medicine medicine.disease Fibrinogen Thrombomodulin Gastroenterology Small-cell carcinoma 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Internal medicine Medicine business Lung cancer Prospective cohort study medicine.drug
Zdroj:	Thoracic Cancer. 9:931-938
ISSN:	1759-7706
Popis:	BACKGROUND The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lung cancer than in non-lung cancer patients. Moreover, the prevalence of DIC varies among the pathologic types of lung cancer. This study analyzed the relationship between coagulation factors and the pathologic types of lung cancer. METHODS Twenty-six patients with progressive, inoperable stage IIB or higher lung cancer (20 men, 6 women; mean age 71 years; 11 Adeno, 10 squamous cell carcinoma, and 5 small cell carcinoma) and five healthy volunteers without respiratory disease (3 men, 2 women; mean age 72 years) were enrolled in the study. Blood samples were collected at lung cancer diagnosis, before treatment. RESULTS White blood cell count, platelet count, serum C-reactive protein, fibrin/fibrinogen degradation products, fibrinogen, thrombin-antithrombin complex, and D-dimer levels differed significantly between lung cancer patients and the control group, but not among the pathologic types of lung cancer. Thrombomodulin levels were significantly higher in patients with Adeno and squamous cell carcinoma than in those with small cell carcinoma (P < 0.05 and P < 0.01, respectively). Antithrombin levels were significantly lower in patients with squamous cell carcinoma than in those with Adeno (P < 0.05). CONCLUSION Coagulation disorders may develop secondary to chronic inflammation in patients with progressive lung cancer. DIC in lung cancer may be attributed to changes in anticoagulation factors, such as thrombomodulin and antithrombin, but not in other coagulation factors.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8e507cbf226d538b29c474e64289ec53 https://doi.org/10.1111/1759-7714.12766 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.